Third Global Vaccine Congress in Singapore to also feature virtual component

Authoritative speakers present the latest on H1N1 flu vaccines

Amsterdam, 21 September 2009 – Elsevier, a leading publisher of scientific, technical and medical information products and services, announced today, that its journal Vaccine, the most comprehensive and pre-eminent journal for those interested in vaccines and vaccination, will organize the 3rd Vaccine Global Congress from 4-6 October, 2009, in Singapore. For people who cannot attend the congress in Singapore, Elsevier is organizing a Vaccine Virtual counterpart. This truly interactive event will allow people to sample the high-quality content and networking opportunities that the congress and exhibition provide from their desk.

Following the successful Second Vaccine Congress held in Boston last year, the meeting in Singapore will again serve as an authoritative international interface between academics in research and development, regulatory and governmental agencies, charities, and health and industry professionals.

The 3rd Vaccine Global Congress is organized in collaboration with the International Society for Vaccines. At the congress, both GSK and Novartis will present their latest data on H1N1 flu vaccine research. To supplement a number of invited keynote speakers, multiple oral and poster presentations have been selected to cover all facets of vaccinology, including: human vaccines for infectious and non-infectious diseases, veterinary vaccines, adjuvants, drug delivery, production, safety and regulatory aspects.

In addition, Elsevier is offering a taste of the 3rd Vaccine Global Congress by video broadcasting live and on-demand keynote presentations and related Q&A, scheduled on the 5th and 7th of October, respectively. Virtual delegates will be able to attend presentations from top international speakers, submit questions in real time, network and chat with their online peers, and navigate the show via a virtual fully interactive platform. Registration for the Vaccine Virtual Congress is free for the first 250 registrants.

“The Vaccine Congress is again featuring a high diversity of talks”, stated Floris de Hon, Executive Publisher of Vaccine. “Following the success of last year’s virtual congress, I am confident that this year’s event will provide delegates with an excellent environment to access high quality content, assisting in accelerating progress in the development of vaccines”.

# # #

About Vaccine
Vaccine is the pre-eminent journal for those interested in vaccines and vaccination. It serves as an interface between academics, those in research and development, and workers in the field. Relevant topics range from basic research through to applications, safety and legislation.

About Elsevier
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Research Intelligence and ClinicalKey— and publishes over 2,500 journals, including The Lancet and Cell, and more than 35,000 book titles, including a number of iconic reference works. Elsevier is part of RELX Group, a world-leading provider of information and analytics for professional and business customers across industries.

Media Contact:
Anna Hogrebe
+31 20 485 3269